Can Viking Therapeutics (VKTX) Justify Its Valuation On The VK2735 Oral Study Launch?

Viking Therapeutics (VKTX) is back in focus after the company kicked off an exploratory oral maintenance dosing study for VK2735, its dual GLP-1/GIP obesity candidate, following earlier positive maintenance data.

Investors have seen sharp swings in Viking Therapeutics this year, with the 1-day share price return of 2.81% coming against a wider backdrop where the 30-day share price return is down 10.85% and the year-to-date share price return has fallen 19.51%. At the same time, the 3-year total shareholder return of about 160% and 5-year total shareholder return of roughly 374% have kept longer term momentum intact. This suggests that recent weakness may reflect shifting expectations and risk perceptions around the obesity pipeline rather than a simple break in the broader story.

Scan beyond Viking Therapeutics and compare this obesity story with other high-conviction healthcare opportunities using our curated list of 34 healthcare AI stocks.

After a near 20% slide this year against analyst estimates that cluster far above the current US$28.51 price, where does fair value for Viking Therapeutics really land in that gap between quotes and models?

Preferred Price-to-Book of 8.1x: Is it justified?

Viking Therapeutics trades at $28.51 with a P/B ratio of 8.1x, which sets a high bar for a business that is still in the development stage and not yet producing meaningful revenue.

The P/B multiple compares the market value of the equity to its book value. At 8.1x investors are paying a sizeable premium over the company’s net assets on the balance sheet.

For a clinical-stage biotech like Viking Therapeutics that reported a loss of $534.796k and makes less than $1m in revenue, such a premium usually reflects confidence in the pipeline, not current earnings power.

The gap between Viking Therapeutics and peers is wide, with the stock described as expensive both relative to the peer group average P/B of 7.2x and versus the broader US Biotechs industry average of 2.1x. This signals that the market is assigning materially richer expectations to this ticker than to the sector overall.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 8.1x (OVERVALUED)

Still, the story around Viking Therapeutics could shift quickly if clinical trial timelines slip, or if fresh capital raises dilute existing shareholders.

Find out about the key risks to this Viking Therapeutics narrative.

Another View: DCF Points to a Very Different Price

The story looks different when you switch from Viking Therapeutics’ 8.1x P/B multiple to our DCF model. On that framework, the SWS DCF model points to a future cash flow value of $7.64 while the stock trades at $28.51. That gap suggests investors are paying well above what the cash flow math implies. Which lens do you trust more?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viking Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 29 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution around Viking Therapeutics feels familiar, treat it as a prompt to scrutinize the data and form your own stance quickly. A good place to start is by weighing the 4 important warning signs.

Looking for more Viking Therapeutics style investment ideas?

If you want to stress test your view on Viking Therapeutics, comparing it with other opportunities through a structured search can sharpen your next move.

• Target potential mispricings by filtering for companies that combine quality fundamentals with appealing valuations using our 29 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with robust finances and cleaner balance sheets through the list of solid balance sheet and fundamentals (25 results).
• Tilt toward stability and income by scanning for higher yielding payers that still keep risk controls in view using the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com